A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: Functional characterization.

In multiple endocrine neoplasia (MEN), REarranged during Transfection (RET) gene testing has been extensively exploited to characterize tumor aggressiveness and optimize the diagnostic and clinical management. Objective: To report the underlying genetic alterations in an unusual case of MEN type 2 (MEN-2A). Design and Patient: Occult medullary thyroid carcinoma (MTC) was diagnosed in 44-year-old male who had presented with unilateral phaeochromcytoma. DNA extracted from the blood and tumor tissues was analyzed for mutations in RET. The transforming potential and mitogenic properties of the identified RET mutation were investigated. Results: The patient carried a novel heterozygous germ-line RET mutation in exon 5 (Val292Met, GTG>ATG) (V292M/RET) with no evidence of additional somatic alterations. The mutation maps to the third cadherin-like domain of RET, which is usually not included in RET screening. Interestingly, MTC with concomitant phaeochromcytoma has never been associated with a RET mutation involving the extracellular cadherin-like domain. V292M/RET was absent in the only 2 relatives examined. In vitro assays indicate that the mutant has low-grade transforming potential. Conclusions: Complete characterization and classification of all novel RET mutations is essential for extending genetic analysis in clinical practice. Our findings suggest that: 1) in all MEN-2 patients negative for RET hot-spot mutations, testing should be extended to all coding regions of the gene; 2) the newly identified V292M/RET mutation is characterized by relatively weak in vitro transforming ability.